|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:1993
gptkb:FDA
|
|
gptkbp:atccode
|
N03 AX12
|
|
gptkbp:available_on
|
generic version
|
|
gptkbp:bioavailability
|
27% to 60%
|
|
gptkbp:brand
|
gptkb:Neurontin
gptkb:Gralise
gptkb:Horizant
|
|
gptkbp:casnumber
|
60142-96-3
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:chemical_formula
|
C9 H17 N1 O2
|
|
gptkbp:clinical_trial
|
pain management
epilepsy treatment
anxiety treatment
|
|
gptkbp:contraindication
|
hypersensitivity
severe renal impairment
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
gptkb:Software_Solutions
gptkb:tablet
gptkb:capsule
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Neurontin
|
|
gptkbp:ingredients
|
gptkb:gabapentin
|
|
gptkbp:interacts_with
|
antacids
CNS depressants
opioids
|
|
gptkbp:legal_status
|
prescription only
|
|
gptkbp:lifespan
|
5 to 7 hours
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:India
gptkb:United_States
|
|
gptkbp:metabolism
|
not significantly metabolized
|
|
gptkbp:previous_name
|
gptkb:gabapentin
2-(1-oxononyl)pentanoic acid
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
dizziness
fatigue
nausea
swelling
drowsiness
|
|
gptkbp:used_for
|
gptkb:epilepsy
anxiety disorders
neuropathic pain
|
|
gptkbp:bfsParent
|
gptkb:Gabapentin
|
|
gptkbp:bfsLayer
|
6
|